Medecine et maladies infectieuses · 2017
HPV test by Hybrid Capture II for the diagnosis of HR-HPV persistent infection.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Serour Y, Bendahmane M, Abbou Baker F, Medles M, Moueddene B, Kraiba R
Аннотация
INTRODUCTION: Persistent high-risk HPV (HR-HPV) infection is associated with a greater risk of cervical cancer.
PATIENTS AND METHODS: Statistical data on the prevalence of HR-HPV infections in the Algerian population is lacking. We conducted a prospective study of 300 women aged between 25 and 50 years, screened for cervical cancer from 2012 to 2015 in Sidi Bel Abbès, a western region of Algeria. We aimed to assess the reliability of the repeated use of the HC II test (three longitudinal HPV tests 9 months apart from each other) in diagnosing the persistence of HR-HPV infection.
RESULTS: The prevalence of HR-HPV infection was 7.33% and infected women were aged 37.9±3years. For 90.9% of HR-HPV-positive patients, the infection persisted for a mean of 18.5months [95% CI: 16.9-22.1months]. Among these patients, 55.55% developed CIN1 and 11.11% developed CIN2. The sensitivity of the HC II test was 81.74% [95% CI: 71.3-89.6] and its positive predictive value associated with abnormal cervical biopsy was 27.49% [95% CI: 16.0-33.33].
CONCLUSION: Repeating the HC II test is a good predictor for identifying women at high risk of cervical cancer.
PATIENTS AND METHODS: Statistical data on the prevalence of HR-HPV infections in the Algerian population is lacking. We conducted a prospective study of 300 women aged between 25 and 50 years, screened for cervical cancer from 2012 to 2015 in Sidi Bel Abbès, a western region of Algeria. We aimed to assess the reliability of the repeated use of the HC II test (three longitudinal HPV tests 9 months apart from each other) in diagnosing the persistence of HR-HPV infection.
RESULTS: The prevalence of HR-HPV infection was 7.33% and infected women were aged 37.9±3years. For 90.9% of HR-HPV-positive patients, the infection persisted for a mean of 18.5months [95% CI: 16.9-22.1months]. Among these patients, 55.55% developed CIN1 and 11.11% developed CIN2. The sensitivity of the HC II test was 81.74% [95% CI: 71.3-89.6] and its positive predictive value associated with abnormal cervical biopsy was 27.49% [95% CI: 16.0-33.33].
CONCLUSION: Repeating the HC II test is a good predictor for identifying women at high risk of cervical cancer.
Предметные рубрики MeSH
AdultAlgeriaBiopsyCervix UteriColposcopyDNA Probes, HPVFemaleHumansLuminescent MeasurementsMiddle AgedNucleic Acid HybridizationPapillomavirus InfectionsPrecancerous ConditionsProspective StudiesRNA ProbesReproducibility of ResultsRiskSensitivity and SpecificityUterine Cervical NeoplasmsUterine Cervical Dysplasia